Navigation Links
Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Date:9/2/2008

ere 1.406 and 1.199L for ACCLAIM/COPD I and ACCLAIM/COPD II, respectively. Patients were randomized to receive aclidinium bromide (200 micrograms once daily) or placebo over a one-year treatment period.

The primary endpoints for ACCLAIM/COPD I and II were bronchodilation at the end of the dosing interval, assessed as trough FEV1 (measured at 23-24h post-dose). For both trials, the primary endpoint was measured at week 12 and week 28 to fulfill FDA and European requirements, respectively.

Aclidinium bromide and placebo were administered to patients using the Genuair(R)(1) device, a multi-dose dry powder inhaler which operates by a 'one press and inhale' technique.

Overall, safety and tolerability were comparable between aclidinium and placebo in terms of percentage of patients with Serious Adverse Events (aclidinium: 9.1%, placebo 10.7%), Fatal Adverse Events (aclidinium: 1.1%, placebo: 1.7%), or with Adverse Events leading to treatment discontinuation (aclidinium: 4.0%, placebo: 5.7%). The most frequently reported adverse events across both studies were nasopharyngitis (aclidinium: 14.5%, placebo: 12.9%) and headache (aclidinium: 12.7%, placebo: 12.6%). Potential anticholinergic adverse events were observed in a similarly low percentage of patients, (e.g. dry mouth - aclidinium: 0.7%, placebo: 1.2%).

"Almirall remains committed to continue the efforts to provide treatment options for COPD patients with aclidinium bromide", commented Jorge Gallardo, Chairman and Chief Executive Officer of Almirall.

About COPD

The World Health Organisation (WHO) has described COPD as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.

The most
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. Browse the full ...
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... , , STAMFORD, Conn. , Feb. ... subsidiary of Speedus Corp. (Nasdaq: SPDE ), was jointly named ... February 11th—the 163rd birthday of renowned inventor Thomas Alva Edison—at a ... City . Edison created many of the products and technologies taken ...
... , , REDWOOD CITY, Calif. , Feb. ... collaborations in pharmaceutical manufacturing with Dishman Pharmaceuticals and Chemicals ... American Pacific Corporation. These agreements expand the application of ... pharmaceutical products. , Under the new agreements, Codexis ...
Cached Medicine Technology:Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 2Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 3Codexis Expands Pharmaceutical Manufacturing Partnerships 2Codexis Expands Pharmaceutical Manufacturing Partnerships 3
(Date:7/12/2014)... Pittsburgh, PA (PRWEB) July 12, 2014 "The ... so it’s uncomfortable and painful to wear shoes," said an ... a special sock that prevents this from happening. , He ... an effective way to prevent the second and big toes ... more endurance while wearing shoes. Ergonomic and easy to use, ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of ... the use of his left side. Eating became a difficult task ... people like them enjoy eating again,” said an inventor, from Fayetteville, ... CAROL HALL PLATE (P C H PLATE). , The PATRICIA CAROL ... to eat for individuals who suffer from stroke, experience tremors or ...
(Date:7/12/2014)... New York, New York (PRWEB) July 12, 2014 ... ) continue to move forward in U.S. courts, Bernstein ... that ties elevated metal ion levels to the failure ... the July 2nd issue of The Journal of Bone ... had received unilateral Articular Surface Replacement prostheses at ...
(Date:7/12/2014)... Beverly Hills, CA (PRWEB) July 12, 2014 ... reason why are bodies can readily absorb the nutrients in ... into tiny particles that are small enough to be absorbed ... the DZ10 team, a lack of enzymes in regular food ... DZ10 is a product that was started by Michelle DelPresto, ...
(Date:7/12/2014)... Albany, NY (PRWEB) July 12, 2014 ... to 2020 - New and Late-Stage Four-Factor PCCs ... in-depth analysis of the critical care market in ... and Canada. The report provides an estimation of ... to 2020. It covers critical care indications that ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... French . , Recent animal studies have ... used to treat diarrhea and other gastrointestinal disorders ... diseases. Scientists, however, had a variety of theories to ... such similar effects on three unrelated neurodegenerative disorders. , ...
... AMERIGROUP Corporation (NYSE: AGP ) today announced that ... Conference on January 14 in San Francisco.A live broadcast of ... p.m. Eastern Time, can be accessed on AMERIGROUP,s Web site, ... be available for 30 days, and can be accessed at ...
... Jan. 6, Halo Pharmaceutical, Inc., a privately ... completion of its acquisition of the Whippany-NJ Manufacturing ... ABT ). At over 200,000 square feet, ... including an impressive array of formulation services, operations ...
... remain stableWASHINGTON, Jan. 6 Karen Ignagni, President and CEO ... data released by CMS today showing that health spending in ... decade at 6.1 percent in 2007. According to the ... 2007, the same rate as in 2006, but much lower ...
... UCSF has received a $7.5 million grant from the Bill & ... to help address Africa,s urgent need for healthcare workers. , ... ... San Francisco has received a $7.5 million grant from the Bill ...
... With 30 million drivers in the US aged 65 ... they can no longer drive safely and decide that it,s ... that a decrease in vision function is a key factor ... and Driving Study (SEEDS) ( http://www.iovs.org/cgi/content/full/50/1/107 ), conducted by researchers ...
Cached Medicine News:Health News:Old gastrointestinal drug slows aging, McGill researchers say 2Health News:Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott 2Health News:Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott 3Health News:AHIP Statement on National Health Expenditure Data 2Health News:UCSF and Muhimbili University Launch Initiative to Strengthen Tanzanian Health Workforce 2Health News:UCSF and Muhimbili University Launch Initiative to Strengthen Tanzanian Health Workforce 3Health News:Vision problems prompt older drivers to put down the keys 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: